TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

RECRUITING

I'm interested ...!!

Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.

Conditions:

🦠 Colorectal Cancer; Lung Cancer

🗓️ Study Start (Actual) 20 May 2021

🗓️ Primary Completion (Estimated) 30 October 2025

✅ Study Completion (Estimated) 31 December 2025

👥 Enrollment (Estimated) 110

🔬 Study Type INTERVENTIONAL

📊 Phase PHASE2

Locations:

📍 Orange, California, United States

📍 Hsinchu, Taiwan

📍 Taichung, Taiwan

📋 Eligibility Criteria

Description

Inclusion Criteria:

* Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
* mCRC progressed on at least two lines of standard chemotherapy; or
* NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
* Measurable disease
* ECOG 0-1
* At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
* Adequate organ function

Exclusion Criteria:

* Prior organ transplantation
* Liver metastasis more than 50%
* Oxygen saturation less than 92% in room air
* Prior autoimmune disorder
* CNS metastasis
* Major GI bleeding in the last 2 months

Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)

Sexes Eligible for Study: ALL

Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted 6 January 2021
First Submitted that Met QC Criteria 7 January 2021
First Posted 8 January 2021

Study Record Updates

Last Update Submitted that Met QC Criteria 18 September 2023
Last Update Posted 21 September 2023
Last Verified September 2023